Aktis Oncology (AKTS) expects to raise $200.60 million in an initial public offering on Friday, January 9th, IPO Scoop reports. The company will issue 11,800,000 shares at a price of $16.00-$18.00 per share.
In the last twelve months, Aktis Oncology generated $5.56 million in revenue and had a net loss of $60.65 million. Aktis Oncology has a market cap of $793 million.
J.P.Morgan, BofA Securities, Leerink Partners and TD Cowen acted as the underwriters for the IPO.
Aktis Oncology provided the following description of their company for its IPO: “(Incorporated in Delaware) We are a clinical oncology company developing radiopharmaceuticals to treat solid tumors. Our lead drug candidates are: -Ac-AKY-1189 to treat cancers that express Nectin-4 – We are now enrolling 150 patients in a Phase 1B trials with preliminary results expected in the first quarter of 2027, and –Ac-AKY-2519 to treat tumors that express B7-H3 – We plan to submit an IND filing in 2026. Note: Net loss and revenue are for the 12 months that ended Sept. 30, 2025. (Note: Aktis Oncology disclosed the terms for its IPO in an S-1/A filing dated Jan. 5, 2026: The company is offering 11.78 million shares (11,775,000 shares) at a price range of $16.00 to $18.00 to raise $200.18 million, if priced at the $17.00 mid-point of its range. Background: Aktis Oncology filed its S-1 for its IPO on Dec. 19, 2025, without disclosing the terms. Estimated proceeds are $100 million, a placeholder figure.)Â “.
Aktis Oncology was founded in 2020 and has employees. The company is located at 17 Drydock Avenue, Suite 17-401 Boston, Massachusetts 02210 and can be reached via phone at (617) 461-4023.
Receive News & Ratings for Aktis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aktis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
